Kaempferol [520-18-3]

Referência HY-14590-100mg

Tamanho : 100mg

Marca : MedChemExpress

Contactar o distribuidor local :


Telefone : +1 850 650 7790

Description

Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer[1][2][3][4].

IC50 & Target[1]

ERα

 

Human Endogenous Metabolite

 

Cellular Effect
Cell Line Type Value Description References
A-375 IC50
12.05 ng/mL
Compound: 10
Cytotoxicity in human A375 cells
Cytotoxicity in human A375 cells
[PMID: 28793973]
A-431 IC50
3 μg/mL
Compound: 16
Inhibition of EGFR in human A431 cells
Inhibition of EGFR in human A431 cells
[PMID: 1479375]
A549 IC50
>1 x 10-4M
Compound: 7
Cytotoxicity against human A549 cells after 72 hrs by XTT assay
Cytotoxicity against human A549 cells after 72 hrs by XTT assay
[PMID: 20619940]
A549 IC50
>10 μM
Compound: 2
Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay
Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay
[PMID: 33979163]
A549 IC50
>10 μM
Compound: 5
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
[PMID: 28165740]
A549 IC50
>10 x 10-5M
Compound: 7
Cytotoxicity against human A549 cells after 72 hrs by XTT assay
Cytotoxicity against human A549 cells after 72 hrs by XTT assay
[PMID: 20619940]
A549 IC50
>20 μg/mL
Compound: Kaempferol
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
[PMID: 21106454]
A549 IC50
>10 × 10-5M
Compound: 7
Cytotoxicity against human A549 cells after 72 hrs by XTT assay
Cytotoxicity against human A549 cells after 72 hrs by XTT assay
[PMID: 20619940]
B16 IC50
20 μM
Compound: 10
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs
[PMID: 19615910]
B16 IC50
53.7 μM
Compound: 11
Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay
[PMID: 25659770]
B16-4A5 IC50
25 μM
Compound: 16
Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs
Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs
[PMID: 20189399]
B16-4A5 IC50
88 μM
Compound: 10
Inhibition of theophylline-stimulated mouse B16-4A5 cell proliferation assessed as cell viability after 68 hrs by WST8 assay
Inhibition of theophylline-stimulated mouse B16-4A5 cell proliferation assessed as cell viability after 68 hrs by WST8 assay
[PMID: 19615910]
BEAS-2B IC50
0.35 mM
Compound: 2
Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 33231455]
BGC-823 IC50
>10 μM
Compound: 2
Cytotoxicity against human BGC-823 cells measured after 48 hrs by MTT assay
Cytotoxicity against human BGC-823 cells measured after 48 hrs by MTT assay
[PMID: 33979163]
BT-549 IC50
>10 μM
Compound: 5
Cytotoxicity against human BT549 cells after 48 hrs by SRB assay
Cytotoxicity against human BT549 cells after 48 hrs by SRB assay
[PMID: 28165740]
BV-2 IC50
10.59 μM
Compound: 97
Anti-inflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced NO production
Anti-inflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced NO production
[PMID: 37683361]
BV-2 IC50
52.4 μM
Compound: 97
Anti-inflammatory activity against mouse BV-2 cells assessed as inhibition of LPS-induced PGE2 production pretreated for 2 hrs followed stimulated with LPS for 22 hrs by ELISA analysis
Anti-inflammatory activity against mouse BV-2 cells assessed as inhibition of LPS-induced PGE2 production pretreated for 2 hrs followed stimulated with LPS for 22 hrs by ELISA analysis
[PMID: 37683361]
BV-2 IC50
60.1 μM
Compound: 97
Anti-inflammatory activity against mouse BV-2 cells assessed as inhibition of LPS-induced COX-2 expression pretreated for 2 hrs followed stimulated with LPS for 22 hrs by ELISA analysis
Anti-inflammatory activity against mouse BV-2 cells assessed as inhibition of LPS-induced COX-2 expression pretreated for 2 hrs followed stimulated with LPS for 22 hrs by ELISA analysis
[PMID: 37683361]
BV-2 IC50
8.86 μM
Compound: 5
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay
[PMID: 28165740]
BV-2 IC50
80.8 μM
Compound: 97
Anti-inflammatory activity against mouse BV-2 cells assessed as inhibition of LPS-induced IL-1beta secretion pretreated for 2 hrs followed stimulated with LPS for 22 hrs by ELISA analysis
Anti-inflammatory activity against mouse BV-2 cells assessed as inhibition of LPS-induced IL-1beta secretion pretreated for 2 hrs followed stimulated with LPS for 22 hrs by ELISA analysis
[PMID: 37683361]
BV-2 IC50
80.8 μM
Compound: 97
Anti-inflammatory activity against mouse BV-2 cells assessed as inhibition of LPS-induced IL-6 pre-treated for 2 hrs followed stimulated with LPS for 22 hrs
Anti-inflammatory activity against mouse BV-2 cells assessed as inhibition of LPS-induced IL-6 pre-treated for 2 hrs followed stimulated with LPS for 22 hrs
[PMID: 37683361]
Ca9-22 IC50
>20 μg/mL
Compound: Kaempferol
Cytotoxicity against human Ca9-22 cells by MTT assay
Cytotoxicity against human Ca9-22 cells by MTT assay
[PMID: 21106454]
CHO-K1 IC50
0.24 mM
Compound: 2
Cytotoxicity against CHO-K1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against CHO-K1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 33231455]
CWR22R IC50
>40 μM
Compound: 19
Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer
Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer
[PMID: 22789812]
HCC1937 IC50
>10 μM
Compound: 2
Cytotoxicity against human HCC1937 cells measured after 48 hrs by MTT assay
Cytotoxicity against human HCC1937 cells measured after 48 hrs by MTT assay
[PMID: 33979163]
HCT-116 IC50
>10 μM
Compound: 2
Cytotoxicity against human HCT-116 cells measured after 48 hrs by MTT assay
Cytotoxicity against human HCT-116 cells measured after 48 hrs by MTT assay
[PMID: 33979163]
HEK293 IC50
0.36 μM
Compound: 19
Inhibition of human recombinant 17beta-HSD2 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol
Inhibition of human recombinant 17beta-HSD2 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol
[PMID: 18533708]
HEK293 IC50
1.05 μM
Compound: 19
Inhibition of human recombinant 17beta-HSD1 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol
Inhibition of human recombinant 17beta-HSD1 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol
[PMID: 18533708]
HEK293 IC50
1.2 μM
Compound: 7h
Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay
Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay
[PMID: 20731357]
HEK293 IC50
3.9 μM
Compound: 21
Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay
Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay
[PMID: 30943030]
HeLa IC50
>1 x 10-4M
Compound: 7
Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
[PMID: 20619940]
HeLa IC50
>10 x 10-5M
Compound: 7
Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
[PMID: 20619940]
HeLa IC50
>10 × 10-5M
Compound: 7
Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
[PMID: 20619940]
HeLa IC50
2.4 μg/mL
Compound: 6
Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA
Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA
[PMID: 19942440]
Hep 3B2 IC50
17.74 μg/mL
Compound: Kaempferol
Cytotoxicity against human Hep3B cells by MTT assay
Cytotoxicity against human Hep3B cells by MTT assay
[PMID: 21106454]
HepG2 EC50
7.74 μM
Compound: Kaempferol
Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay
Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay
[PMID: 26974372]
HepG2 EC50
7.74 μmol
Compound: Kaempferol
Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay
Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay
[PMID: 26974372]
HepG2 IC50
>10 μM
Compound: 2
Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay
[PMID: 33979163]
HepG2 IC50
>20 μg/mL
Compound: Kaempferol
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
[PMID: 21106454]
HepG2 IC50
>400 μM
Compound: 33
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
[PMID: 21726077]
HepG2 IC50
20.5 μM
Compound: 97
Anti-inflammatory activity against TNFalpha-induced human HepG2 cells assessed as inhibition of NF-kappaB activity pre-indubated for 1 hr followed by TNFalpha treatment measured for 5 hrs by luciferase based assay
Anti-inflammatory activity against TNFalpha-induced human HepG2 cells assessed as inhibition of NF-kappaB activity pre-indubated for 1 hr followed by TNFalpha treatment measured for 5 hrs by luciferase based assay
[PMID: 37683361]
HepG2 IC50
9.64 μM
Compound: 5
Inverse agonist activity at human GAL4-DBD-fused ERRalpha-LBD transfected in human HepG2 cells assessed as disruption of interaction with PGC-1alpha after 24 hrs by dual luciferase reporter gene assay
Inverse agonist activity at human GAL4-DBD-fused ERRalpha-LBD transfected in human HepG2 cells assessed as disruption of interaction with PGC-1alpha after 24 hrs by dual luciferase reporter gene assay
[PMID: 23656512]
HL-60 IC50
10 μg/mL
Compound: 9
Antioxidant activity in human HL60 cells assessed as reduction of cytochrome-c release
Antioxidant activity in human HL60 cells assessed as reduction of cytochrome-c release
[PMID: 10650074]
HT-29 IC50
>1 x 10-4M
Compound: 7
Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay
[PMID: 20619940]
HT-29 IC50
>10 x 10-5M
Compound: 7
Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay
[PMID: 20619940]
HT-29 IC50
>10 × 10-5M
Compound: 7
Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay
[PMID: 20619940]
Huh-7 CC50
>50 μM
Compound: 26
Cytotoxicity against human Huh7.5.1 cells by MTT assay
Cytotoxicity against human Huh7.5.1 cells by MTT assay
[PMID: 22445328]
HUVEC IC50
10 μM
Compound: 5, Kaempferol
Inhibition of NADPH oxidase in Homo sapiens (human) HUVEC cells
Inhibition of NADPH oxidase in Homo sapiens (human) HUVEC cells
10.1007/s00044-012-0353-y
J774.2 IC50
53.67 μM
Compound: 1
Cytotoxicity against BALB/c mouse J774.2 cells after 72 hrs by trypan blue assay
Cytotoxicity against BALB/c mouse J774.2 cells after 72 hrs by trypan blue assay
[PMID: 19489596]
Jurkat IC50
10.5 μM
Compound: Kaempferol
Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method
Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method
[PMID: 30776692]
Jurkat IC50
11 μM
Compound: Kaempferol
Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method
Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method
[PMID: 30776692]
L929 EC50
20 μM
Compound: kaempferol
Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining
Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining
[PMID: 9287415]
L929 EC50
25 μM
Compound: kaempferol
Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay
Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay
[PMID: 9287415]
MCF7 IC50
>10 μM
Compound: 2
Cytotoxicity against human MCF7 cells measured after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells measured after 48 hrs by MTT assay
[PMID: 33979163]
MCF7 IC50
>20 μg/mL
Compound: Kaempferol
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
[PMID: 21106454]
MCF7 IC50
50 μM
Compound: Kaempferol
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay
[PMID: 33257172]
MCF7 IC50
6.2 μM
Compound: 12
Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
[PMID: 21354800]
MDA-MB-231 IC50
>20 μg/mL
Compound: Kaempferol
Cytotoxicity against human MDA-MB-231 cells by MTT assay
Cytotoxicity against human MDA-MB-231 cells by MTT assay
[PMID: 21106454]
MDCK CC50
>300 μM
Compound: 3
Cytotoxicity against MDCK cells after 48 hrs by MTT assay
Cytotoxicity against MDCK cells after 48 hrs by MTT assay
[PMID: 19729316]
MDCK CC50
581.3 μM
Compound: Kaempferol
Cytotoxicity against MDCK cells
Cytotoxicity against MDCK cells
[PMID: 25096296]
MDCK EC50
18.5 μM
Compound: 3
Antiviral activity against influenza A virus H9N2 A/Chicken/Korea/MS96/96 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect
Antiviral activity against influenza A virus H9N2 A/Chicken/Korea/MS96/96 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect
[PMID: 19729316]
MDCK EC50
30.2 μM
Compound: 3
Antiviral activity against influenza A virus H1N1 A/PR/8/34 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect
Antiviral activity against influenza A virus H1N1 A/PR/8/34 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect
[PMID: 19729316]
MDCK IC50
4.7 μM
Compound: 12
Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
[PMID: 21354800]
Monocyte IC50
2.7 μM
Compound: kaempferol
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
[PMID: 8882428]
Monocyte IC50
2.7 × 10-6M
Compound: kaempferol
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
[PMID: 8882428]
Monocyte IC50
2.7 x 10-6M
Compound: kaempferol
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
[PMID: 8882428]
Monocyte IC50
20 μM
Compound: Kaempferol
Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA
Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA
[PMID: 10096854]
MV4-11 GI50
3.34 μM
Compound: 5
Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay
Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay
[PMID: 23411073]
Osteoclast IC50
1.6 μM
Compound: kaempferol
Induction of mouse osteoclast apoptosis
Induction of mouse osteoclast apoptosis
[PMID: 17994703]
P388 ED50
6.7 μg/mL
Compound: Kaempferol
Cytotoxicity against mouse P388 cells
Cytotoxicity against mouse P388 cells
[PMID: 3404159]
Peritoneal macrophage IC50
29 μM
Compound: 5; kp19
Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method
Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method
[PMID: 27955927]
Platelet IC50
>50 μg/mL
Compound: Kaempferol
Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry
Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry
[PMID: 21106454]
Platelet IC50
3.55 μg/mL
Compound: Kaempferol
Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry
Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry
[PMID: 21106454]
RAW264.7 IC50
<15 μM
Compound: kaempherol
Inhibition of COX2 mRNA expression in mouse RAW264.7 cells
Inhibition of COX2 mRNA expression in mouse RAW264.7 cells
[PMID: 16038536]
RAW264.7 IC50
13.3 μM
Compound: 97
Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-stimulated IL-6 mRNA level incubated for 3 hrs by RT-qPCR analysis
Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-stimulated IL-6 mRNA level incubated for 3 hrs by RT-qPCR analysis
[PMID: 37683361]
RAW264.7 IC50
13.4 μM
Compound: 5; kp19
Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells by Griess method
Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells by Griess method
[PMID: 27955927]
RAW264.7 IC50
13.4 μM
Compound: Kaempferol
Inhibition of LPS-stimulated nitric oxide production in rat RAW264.7 cells pretreated for 2 hrs followed by LPS-stimulation after 16 hrs by Griess assay
Inhibition of LPS-stimulated nitric oxide production in rat RAW264.7 cells pretreated for 2 hrs followed by LPS-stimulation after 16 hrs by Griess assay
[PMID: 28662961]
RAW264.7 IC50
13.4 μM
Compound: 5; kp19
Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells by Greiss method
Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells by Greiss method
[PMID: 27955927]
RAW264.7 IC50
14.13 μM
Compound: 97
Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production by ELISA analysis
Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production by ELISA analysis
[PMID: 37683361]
RAW264.7 IC50
15 μM
Compound: 5; kp19
Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells measured after 16 hrs
Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells measured after 16 hrs
[PMID: 27955927]
RAW264.7 IC50
17 μM
Compound: 5; kp19
Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells by Griess method
Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells by Griess method
[PMID: 27955927]
RAW264.7 IC50
17 μM
Compound: 5; kp19
Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells by Greiss method
Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells by Greiss method
[PMID: 27955927]
RAW264.7 IC50
60.2 μM
Compound: 7
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
[PMID: 21353543]
RAW264.7 IC50
80.3 μM
Compound: 7
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs
[PMID: 21353543]
RS4-11 GI50
>50 μM
Compound: 5
Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay
Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay
[PMID: 23411073]
Sf21 IC50
>100 μM
Compound: 6
Inhibition of human recombinant COX2 expressed in insect Sf21 cells by EIA assay
Inhibition of human recombinant COX2 expressed in insect Sf21 cells by EIA assay
[PMID: 17378609]
SK-MEL-2 IC50
>10 μM
Compound: 5
Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay
Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay
[PMID: 28165740]
SK-OV-3 IC50
>10 μM
Compound: 5
Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
[PMID: 28165740]
THP-1 IC50
15.92 μM
Compound: 97
Anti-inflammatory activity in human THP-1 cells assessed as inhibition of LPS-stimulated NO production by ELISA analysis
Anti-inflammatory activity in human THP-1 cells assessed as inhibition of LPS-stimulated NO production by ELISA analysis
[PMID: 37683361]
Vero CC50
91.5 μg/mL
Compound: kaempferol
Cytotoxicity against african green monkey Vero cells
Cytotoxicity against african green monkey Vero cells
[PMID: 1338212]
In Vitro

Kaempferol also has anti-inflammatory effects via inhibition of interleukin-4 and cyclo-oxygenase 2 expression by suppressing Src kinase and downregulating the NFκB pathway. Kaempferol is also effective in inhibiting angiogenesis and inducing apoptosis in ovarian cancer cells[1]. Kaempferol is a natural flavonoid that is widely distributed in fruits and vegetables, and prospective studies revealed that over decades, consumption of Kaempferol dramatically and significantly reduces the risk of ovarian cancer in American female nurses. After a 24-hour treatment, Kaempferol causes a significant and concentration-dependent inhibition of proliferation in all 3 ovarian cancer cells tested. This inhibition is observed at 40 μM or higher concentrations of treatment[2]. Kaempferol is a flavonoid which is abundant in a variety of plant derived food and leaves used in traditional medicines. Kaempferol significantly inhibits NADPH oxidase activity. Kaempferol decrease reactive oxygen species (ROS) by directly bound NADPH oxidase. Kaempferol prevents Ang II-induced sinus nodal cell death by lowering CAMKII oxidization[3].10-20 μM Kaempferol dose-dependently suppresses its release in sensitized RBL-2H3 cells. When 10-20 μM Kaempferol is supplemented to DNP-BSA-challenged RBL-2H3 cells for 15 min, the activation of Syk and PLCγ is highly attenuated. When ≥10 μM Kaempferol is added to DNP-BSA-challenged RBL-2H3 cells for 60 min, the COX2 induction is reduced[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The COX2 induction is confirmed in the airways of BSA-challenged BALB/c mice. There is lack of COX2 in airways of untreated control mice observed. The BSA inhalation to mice led to enhanced COX2 induction (dark brown staining) in mouse airway, which is reversed by oral administration of Kaempferol. In BSA-challenged mice, there is a marked goblet cell hyperplasia and epithelial thickening observed. When 20 mg/kg Kaempferol is supplemented to BSA-challenged mice, the epithelial thickening completely disappeared[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique
Masse moléculaire

286.24

Formule

C15H10O6

CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

OC1=C2C(OC(C3=CC=C(O)C=C3)=C(O)C2=O)=CC(O)=C1

Structure Classification
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 1 year
-20°C 6 months
Solvant et solubilité
In Vitro: 

DMSO : 20 mg/mL (69.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.4936 mL 17.4679 mL 34.9357 mL
5 mM 0.6987 mL 3.4936 mL 6.9871 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2 mg/mL (6.99 mM); Clear solution

    This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2 mg/mL (6.99 mM); Clear solution

    This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  50% PEG300    50% Saline

    Solubility: 10 mg/mL (34.94 mM); Suspended solution; Need ultrasonic

  • Protocol 2

    Add each solvent one by one:  0.5% CMC/saline water

    Solubility: 5 mg/mL (17.47 mM); Suspended solution; Need ultrasonic

Pureté et documentation
Références

Você também pode estar interessado nos seguintes produtos:



Referência
Descrição
Cond.
Price Bef. VAT
NB-64-00957-500mg
 500mg 
NB-64-11231-100mg
 100mg